Patient-reported outcome: least square mean change from baseline at week 24 | Methotrexate monotherapy n=284 | Etanercept monotherapy n=284 | Methotrexate+etanercept combination therapy n=283 |
HAQ-DI* | –0.39 | –0.41 | –0.44 |
PtGA* | –22.70 | –31.64† | –29.04‡ |
PtGAJP* | –18.95 | –24.12‡ | –24.90‡ |
SF-36 PCS§ | 5.68 | 7.38‡ | 7.62‡ |
SF-36 MCS§ | 3.48 | 2.99 | 3.46 |
SF-36 domain scores§ | |||
Physical function | 14.47 | 17.42 | 17.54 |
Role physical | 13.81 | 16.28 | 17.66 |
Bodily pain | 16.03 | 20.47‡ | 21.66¶ |
General health | 7.77 | 11.93¶ | 10.9 |
Vitality | 10.46 | 10.99 | 13.94‡ |
Social function | 14.58 | 11.37 | 13.22 |
Role emotional | 8.58 | 9.76 | 8.08 |
Mental health | 6.92 | 7.5 | 8.91 |
*For HAQ-DI, PtGA and PtGAJP, a lower score indicates a more positive health state, so greater negative changes from baseline indicate improvement.
†P value for comparison with methotrexate monotherapy was ≤0.001.
‡P value for comparison with methotrexate monotherapy was ≤0.05.
§For SF-36, a higher score indicates a more positive health state, so greater positive changes from baseline indicate improvement.
¶P value for comparison with methotrexate monotherapy was ≤0.01.
HAQ-DI, Health Assessment Questionnaire-Disability Index; MCS, Mental Component Summary; PCS, Physical Component Summary; PtGA, Patient Global Assessment; PtGAJP, Patient Global Assessment of Joint Pain; SF-36, Medical Outcomes Study Short Form-36 Questionnaire.